维普中文期刊产品整合服务
60篇 您的检索式:作者名="CARTIER D"
    题名 作者 年代 出处 被引量
1Addition of statins to the standard treatment in patients with cirrhosis:Safety and efficacy显示文摘This review summarizes the safety and efficacy of statins in patients with cirrhosis.Due to concerns about the safety of statins in patients with impaired liver function,they have recently been investigated as a potential treatment option in cirrhosis.The most clinically significant adverse event is statin-related myopathy,and this may be related to the high serum statin concentrations in the setting of severely impaired liver function.Rhabdomyolysis is the most serious and potentially life-threatening manifestation.It has recently been demonstrated that the recommended dose of simvastatin in patients with decompensated cirrhosis would be 20 mg/d because higher values,such as 40 mg/d,are associated with many adverse events,especially muscle injury.Likewise,simvastatin should not be administered to patients with Model for End-stage Liver Disease score>12 and/or Child-Pugh class C because of the high risk of severe muscle injury.Due to the pleiotropic effects,the focus on statins has shifted from being considered harmful to something useful.Through these effects,statins could prevent liver-related morbidity and mortality in cirrhotic patients.Observational studies in large populations of patients with cirrhosis have shown that treatment with statins to decrease high cholesterol levels was associated with a reduced risk of hepatic decompensation,hepatocellular carcinoma development and death.The few randomized controlled trials in patients with cirrhosis and portal hypertension showed that statins lower portal pressure,quite likely through a reduction in hepatic resistance.Another large randomized controlled trial in patients with variceal bleeding showed that simvastatin in addition to standard of care did not prevent rebleeding but improved survival rate.Despite these encouraging outcomes,the quality of the evidence regarding the use of statins is low or very low due to the observational characteristics of most of the studies involved.Therefore,it is advisable to perform further randomized controlled trials on a large series of patients with hard clinical endpoints,using different statin types and varying doses.The objectives would be to prevent liver-related morbidity and mortality rather than treating cirrhosis complications to take additional information that makes it possible to add statins to the standard of care of these patients.Alberto E Muñoz Florencia D Pollarsky Mónica Marino Mariano Cartier Horacio Vázquez Pablo Salgado Gustavo Romero 2021World Journal of Gastroenterology2021,27,28:4
2Urinary leukotriene F4 levels during early and late asthmatic responses 显示文摘Manning PJ Rokach J Malo JL Ethier D Cartier A Girard Y Charleson S O'Byrne PM 1990J Allergy Clin Immunol1990,86,2:1
3Quercintrin 3'-sulphate from leaves of Leea guinensis显示文摘Beck P D D B Dijoux M G Cartier G 1998Phytochemistry1998,47,6:1
4Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5-HT4) receptors 显示文摘Guillemot J Compagnon P Cartier D 2009Endocr Relat Cancer2009,16,:1
5Ultrasound of thefetal thymus显示文摘Felker R Cartier M Emerson D Brown D 1989J Ultrasound Med1989,8,12:1
6Overexpression ofserotonin4 receptors in cisapride-responsive adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia causingCushing,s syndrome显示文摘Cartier D Lihrmann I Parmentier F 2003J Clin Endocrinol Metab2003,88,1:1
7Expression profile of serotonin4 ( 5-HT4 ) receptors in adrenocortical aldosteroneproducing adenomas 显示文摘Cartier D Jegou S Parmentier F 2005Eur J Endocrinol2005,153,6:1
8Impact ionization and positive charge formation in silicon dioxide films on silicon 显示文摘 Arnold D Cartier E 1992Appl Phy Lett1992,60,:1
9New syntheses and potential antimalarial activities of new 'retinoid-like chalcones′显示文摘ALAIN V A VALLA B CARTIER D 2006Eur J Med Chem2006,41,:1
10Familial adrenocorticotropin-independent macronodular adrenal hyperplasia with aberrant seroto-nin and vasopressin adrenal receptors显示文摘Vezzosi D Cartier D Régnier C 2007Eur J Endocrinol2007,156,1:1
11Determinants of potency on alpha-conotoxin MII,a peptide antagonist of neuronal nicotinic receptors显示文摘Everhart D Cartier G E Malhotra A 2004Biochemistry2004,43,10:1
12Ef- fective electron mobility in Si inversion layers in metal-oxide semiconductor systems with a high-k insulator: the role o{ re mote phonon scattering 显示文摘FISCHETTI M V NEUMAYER D A CARTIER E A 2001Journal of Applied Physics2001,90,9:1
13Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand inhuman ovarian carcinoma cells显示文摘Lane D Cartier A L'Esperance S 2004Gynecol Oncol2004,93,3:1
14Relative enzymatic ac- tivity, protein stability, and tissue distribution of human steroid - metabolizing UGT2B subfamily members 显示文摘Turgeon D Cartier JS Lvesque E 2001Endocrinology2001,142,2:1
15A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration显示文摘Scott D A Tabarean I Tang Y Cartier A Masliah E Roy S 2010J Neurosci2010,30,:1
16Effective electron mobility in Si inversion layers in metaloxide-semiconductor systems with a high-insulator:The role of remote phonon scattering显示文摘Fischetti M V Neumayer D A Cartier E A 2001J Appl Phys2001,90,9:1
17Reducexi mortality and strokes with off-pump coronary artery bypass grafting surgery in octogenarians显示文摘Demaria RG Carder M Fortier S Martineau R Forticr A Cartier R Pellcrin M He bert Y Bouchard D Page P Pcrrault LP 2002Circulation2002,106,121:1
18Off pump revascularization of multivessel coronary artery disease has a decreased myocardial infarction rate显示文摘Bouchard D Cartier R 1998Eur J Cardiothorac Surg1998,14,1:1
19Quercitrin 3'-sulphate from leaves of Leea guinensis 显示文摘Philippe O D Dijoux M G Cartier G 1998Phytochemsitry1998,47,6:1
20Def'ming Event Reconstruction of Digital Crime Scenes显示文摘Cartier B D Spafford E H 2004Journal of Forensic Sciences2004,49,6:1
返回顶部 每页显示:
共3页 首页 上一页 第1页 下一页 末页 /3 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费